Gilead Sciences
GILD • NASDAQ
Gilead Sciences is a drug manufacturers - general company in the healthcare sector trading on NASDAQ, led by CEO Daniel O'Day, with a market cap of $187.84B.
CEODaniel O'Day
Market Cap$187.84B
Drug Manufacturers - General
Healthcare
Employees18.0K
Websitegilead.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Gilead Sciences
Date
Thursday, April 23, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.88
Revenue Estimate
$6.9B
Earnings History
Past 12 earnings reports for Gilead Sciences
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | Q4 2025 | $1.86Est: $1.83 | +1.6% | $7.9BEst: $7.6B | +3.8% |  10-K |
| Oct 30, 2025 | Q3 2025 | $2.47Est: $2.14 | +15.4% | $7.8BEst: $7.5B | +4.2% | 10-Q |
| Aug 7, 2025 | Q2 2025 | $2.01Est: $1.95 | +3.1% | $7.1BEst: $7.0B | +1.8% | 10-Q |
| Apr 24, 2025 | Q1 2025 | $1.81Est: $1.76 | +2.8% | $6.7BEst: $6.8B | -1.5% | 10-Q |
| Feb 11, 2025 | Q4 2024 | $1.90Est: $1.70 | +11.8% | $7.6BEst: $7.2B | +5.9% | 10-K |
| Nov 6, 2024 | Q3 2024 | $2.02Est: $1.55 | +30.3% | $7.5BEst: $7.0B | +7.8% | 10-Q |
| Aug 8, 2024 | Q2 2024 | $2.01Est: $1.60 | +25.6% | $7.0BEst: $6.7B | +3.5% | 10-Q |
| Apr 25, 2024 | Q1 2024 | -$1.32Est: -$1.49 | +11.4% | $6.7BEst: $6.3B | +5.5% | 10-Q |
| Feb 6, 2024 | Q4 2023 | $1.72Est: $1.78 | -3.4% | $7.1BEst: $7.1B | +0.4% | 10-K |
| Nov 7, 2023 | Q3 2023 | $2.29Est: $1.92 | +19.3% | $7.1BEst: $6.8B | +3.7% | — |
| Aug 3, 2023 | Q2 2023 | $1.34Est: $1.61 | -16.8% | $6.6BEst: $6.4B | +2.6% | 10-Q |
| Apr 27, 2023 | Q1 2023 | $1.37Est: $1.54 | -11.0% | $6.4BEst: $6.3B | +0.3% | — |